Endonovo Therapeutics (ENDV) 10-K 17 Apr 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Apr. 13, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	1,528,172
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 24,485,000
Entity Common Stock, Shares Outstanding		221,543,486
Trading Symbol	ENDV
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 55,533	$ 41,473
Prepaid expenses and other current assets	247,321	336,233
Total current assets	302,854	377,706
Property Plant and Equipment, net	15,825	31,657
Total assets	318,679	409,363
Current Liabilities
Accounts payable and accrued expenses	4,738,333	3,990,185
Short term advances	5,823	3,605
Notes payable, net of discounts of $1,145,849 as of December 31, 2016 and $321,961 as of December 31, 2015	1,878,107	1,261,790
Notes payable - related parties	170,000	245,000
Derivative liability	1,927,752	3,973,542
Current portion of long term loan	12,395	12,031
Total current liabilities	8,721,324	9,486,153
Notes payable, net of discounts of $0 as of December 31, 2016 and $477,346 as of December 31, 2015		27,654
Long term loan	4,221	16,616
Acquisition payable	155,000	155,000
Total liabilities	8,880,545	9,685,423
COMMITMENTS AND CONTINGENCIES
Shareholders' deficit
Super AA super voting preferred stock, $0.0001 par value; 1,000,000 authorized and 1,000 issued and outstanding
Common stock, $.0001 par value; 250,000,000 shares authorized; 134,336,637 and 104,803,401 shares issued and outstanding as of December 31, 2016 and December 31, 2015	13,434	10,479
Additional paid-in capital	9,800,553	3,773,642
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(18,374,283)	(13,058,611)
Total shareholders' deficit	(8,561,866)	(9,276,060)
Total liabilities and shareholders' deficit	$ 318,679	$ 409,363

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Discounts on current notes payable	$ 1,145,849	$ 321,961
Discounts on long term notes payable	$ 0	$ 477,346
Super AA super voting preferred stock, par value	$ 0.0001	$ 0.0001
Super AA super voting preferred stock, authorized	1,000,000	1,000,000
Super AA super voting preferred stock, issued	1,000	1,000
Super AA super voting preferred stock, outstanding	1,000	1,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	134,336,637	104,803,401
Common stock, shares outstanding	134,336,637	104,803,401

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenues, net		$ 4,265
Cost of goods sold		2,162
Gross profit		2,103
Operating expenses	5,410,923	2,566,764
Loss from operations	(5,410,923)	(2,564,661)
Other income (expense)
Change in fair value of derivative liability	2,853,291	(2,531,477)
Gain on settlement of debt	124,888
Loss on extinguishment of debt	(488,149)	(127,674)
Interest expense, net	(2,394,779)	(1,541,924)
Total other income (expense)	95,251	(4,201,075)
Loss before income taxes	(5,315,672)	(6,765,736)
Provision for income taxes
Net loss	$ (5,315,672)	$ (6,765,736)
Basic and diluted loss per share	$ (0.05)	$ (0.07)
Weighted average common share outstanding:
Basic and diluted	117,405,894	96,844,533

Consolidated Statement of Share

Consolidated Statement of Shareholders Deficit - USD ($)	Series AA Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Common Stock Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2014		$ 8,143	$ 1,593,297	$ (1,570)	$ (6,292,875)	$ (4,693,005)
Balance, shares at Dec. 31, 2014	1,000	81,425,957
Shares issued for cash		$ 74	139,017			139,091
Shares issued for cash, shares		752,566
Share issued for services		$ 652	728,098			$ 728,750
Share issued for services, shares		6,519,286				6,519,286
Shares issued with notes payable		$ 185	223,366			$ 223,551
Shares issued with notes payable, shares		1,855,000				1,855,000
Shares issued on extension of notes payable		$ 80	61,670			$ 61,750
Shares issued on extension of notes payable, shares		800,000
Shares issued for conversion of notes payable and accrued interest		$ 1,345	1,028,194			$ 1,029,539
Shares issued for conversion of notes payable and accrued interest, shares		13,450,592				13,450,592
Net loss					(6,765,736)	$ (6,765,736)
Balance at Dec. 31, 2015		$ 10,479	3,773,642	(1,570)	(13,058,611)	(9,276,060)
Balance, shares at Dec. 31, 2015	1,000	104,803,401
Shares issued for cash		$ 57	107,022			$ 107,079
Shares issued for cash, shares		566,327				566,327
Units issued for cash		$ 797	1,127,953			$ 1,128,750
Units issued for cash, shares		7,968,721
Share issued for services		$ 990	2,363,981			2,364,971
Share issued for services, shares		9,888,760
Shares issued with notes payable		$ 14	11,066			$ 11,080
Shares issued with notes payable, shares		140,000				140,000
Shares issued on extension of notes payable		$ 27	111,634			$ 111,661
Shares issued on extension of notes payable, shares		266,617
Shares issued for conversion of notes payable and accrued interest		$ 947	1,956,770			$ 1,957,717
Shares issued for conversion of notes payable and accrued interest, shares		9,476,582				9,476,582
Units issued for conversion of notes payable and accrued interest		$ 123	308,345			$ 308,608
Units issued for conversion of notes payable and accrued interest, shares		1,226,229
Value of warrants issued with note payable			40,000			40,000
Net loss					(5,315,672)	(5,315,672)
Balance at Dec. 31, 2016		$ 13,434	$ 9,800,553	$ (1,570)	$ (18,374,283)	$ (8,561,866)
Balance, shares at Dec. 31, 2016	1,000	134,336,637

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating activities:
Net loss	$ (5,315,672)	$ (6,765,736)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	15,833	14,773
Fair value of notes issued for services		66,667
Fair value of equity issued for services	2,364,971	728,749
Non-cash interest	2,345,699	1,374,487
Change in fair value of derivative liability	(2,853,291)	2,531,477
Loss on extinguishment of liabilities	488,149	127,674
Gain on settlement of debt	(124,888)
Changes in assets and liabilities:
Prepaid expenses and other current assets	86,012	2,000
Accounts payable and accrued expenses	530,853	900,575
Net cash used in operating activities	(2,462,334)	(1,019,334)
Investing activities:
Purchase of property and equipment		(3,829)
Net cash used in investing activities		(3,829)
Financing activities:
Proceeds from the issuance of notes payable	1,491,778	1,036,200
Proceeds from issuance of notes payable- related parties		50,000
Proceeds from short term advances	12,618	100,755
Repayments on short term advances	(103,000)	(100,950)
Proceeds from issuance of common stock	1,235,829	139,092
Payment on notes payable	(166,500)	(138,000)
Payment on notes payable- related parties	(75,000)
Payment on interest payable		(11,773)
Payment against long term loan	(12,031)	(11,676)
Net cash provided by financing activities	2,476,394	1,063,648
Net increase in cash	14,060	40,485
Cash, beginning of year	41,473	988
Cash, end of year	55,533	41,473
Supplemental disclosure of cash flow information:
Cash paid for interest	27,088	11,773
Cash paid for income taxes		500
Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	711,098	544,538
Settlement of notes payable and accrued interest	61,600
Notes payable issued for services	100,000
Accrued interest converted to notes payable	$ 18,448

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Summary of Significant Accounting Policies	Note 1 - Nature of Business and Summary of Significant Accounting Policies Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of the proprietary square wave form device. The Company has historically been involved with intellectual property licensing and commercialization and debt portfolio management.. On January 22, 2014 Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014. Basis of Presentation and Principles of Consolidation The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, and WeHealAnimals, Inc. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has recurring net losses and working capital deficits. The Company has raised approximately $2.7 million in debt and equity financing for the year ended December 31, 2016. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its common stock, has engaged a broker/dealer to raise additional capital and is seeking out profitable companies. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2016, cash and cash equivalents did not exceed FDIC limits. Property plant and equipment Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five and seven years. Expenditures for repairs and maintenance are expensed as incurred. Impairment of Long-lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows generated from the asset group to the recorded value of the asset group. If impairment is indicated, the asset is written down to its estimated fair value. Revenue Recognition The Company recognizes revenue from its technology licensing and commercialization activities in accordance with paragraph 605-10-S99-1 of the FASB Accounting Standards Codification (“ASC”) for revenue recognition. The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the services have been rendered to the customer and accepted by the customer as completed, and (iii) collectability is reasonably assured. Stock-Based Compensation The Company measures stock-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of estimated forfeitures, over the vesting or service period, as applicable, of the stock award using the straight-line method. When our common stock is thinly traded, we have made estimates of the fair value of the common stock based not only on market prices but other factors such as financial condition and results of operations. Income Taxes The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate. Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method, and assumes the exercise or vesting of other dilutive securities, such as options, warrants and restricted stock using the treasury stock method, when dilutive. For the year ended December 31, 2016, the Company had 11,978,455 of weighted-average common shares relating to the convertible debt, under the if-converted method, however, these shares are not dilutive because the Company recorded a loss during the fiscal year. Fair Value of Financial Instruments Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2016 and 2015: Fair Value Measurements at December 31, 2016 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 1,927,752 $ 1,927,752 Total $ - $ - $ 1,927,752 $ 1,927,752 Fair Value Measurements at December 31, 2015 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 3,973,542 $ 3,973,542 Total $ - $ - $ 3,973,542 $ 3,973,542 The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the Derivative Liability Balance December 31, 2014 $ - Issuance of convertible debt 1,922,121 Settlements by debt extinguishment (480,056 ) Change in estimated fair value 2,531,477 Balance December 31, 2015 3,973,542 Issuance of convertible debt 2,525,515 Settlements by debt extinguishment (1,718,013 ) Change in estimated fair value (2,853,292 ) Balance December 31, 2016 $ 1,927,752 Derivative Liability The Company issued Variable Debentures during the years ended December 31, 2016 and 2015, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a derivative liability. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: For Year Ending December 31, 2016 2015 Expected term 1 year - 2 years 9 months - 3 years Exercise price $0.0113-$0.81 $0.03-$0.52 Expected volatility 176%-276% 159%-242% Expected dividends None None Risk-free interest rate 0.45%-1.06% 0.25%-1.06% Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. Recent Accounting Standard Updates In August 2014, the FASB issued FASB ASU2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. FASB ASU 2014-15 changes to the disclosure of uncertainties about an entity’s ability to continue as a going concern. These changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. These changes became effective for the Company for the 2016 annual period. Management has evaluated the impact of the adoption of these changes and has determined there will be no material impact on the consolidated financial statements. This guidance will need to be applied by management at the end of each annual period and interim period therein to determine what, if any, impact there will be on the consolidated financial statements in a given reporting period. In April 2015, the FASB issued ASU No 2015-3, Simplifying the Presentation of Debt Issuance Costs. This update changes the presentation of debt issuance costs in the balance sheet. ASU 2015-03 requires debt issuance costs related to a recognized debt obligation to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. In August 2015, the FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”. This ASU clarified guidance in ASC 2015-03 stating that the SEC staff would not object to a company presenting debt issuance costs related to a line-of-credit arrangement on the balance sheet as a deferred asset, regardless of whether there were any outstanding borrowings at period-end. This update is effective for annual and interim periods beginning after December 15, 2015, which required us to adopt these provisions in the first quarter of 2016. This update was applied on a retrospective basis, wherein the balance sheet of each period presented was adjusted to reflect the effects of applying the new guidance. The adoption of this guidance did not have a material impact on our consolidated financial statements. In November 2015, the FASB issued ASU No 2015-17, Income Taxes (Topic 740). The amendments in ASU 2015-17 change the requirements for the classification of deferred taxes on the balance sheet. Currently, GAAP requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company has early adopted this pronouncement for the fiscal reporting period ended December 31, 2016, and has reclassified the presentation of deferred income taxes in the prior period to conform with the current year classification in the consolidated balance sheets. As a result of the Company having recognized a valuation reserve for the entire deferred tax liability balance at December 31, 2016 and 2015, there is no impact of the presentation of deferred income taxes in our financial statements. In January 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The update intends to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information and addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The new standard affects all entities that hold financial assets or owe financial liabilities. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Management is evaluating the impact of the adoption of these changes will have on the consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2016
License Agreements
License Agreements	Note 2 - License Agreements CPAIR, Inc. Effective November 11, 2011, IPR entered into an Exclusive License Agreement with CPAIR, Inc. (“CPaiR”) to acquire the rights to market and distribute certain intellectual property on a worldwide basis except for the United States. The terms of the license agreement shall be for the greater of the life of the provisional patents, for the technology, or twenty-one years. The term shall automatically renew for an additional one year term unless either party notifies the other that it does not desire to renew the license agreement ninety days before the then-current term of the license agreement expires. Under the Exclusive License Agreement, if IPR enters into a sublicense agreement, IPR is required to pay CPaiR 20% of royalties received by IPR. If IPR elects to distribute the product, without sublicenses, then CPaiR receives 10% of gross revenues. Also, IPR is required to pay to CPaiR 20% of any upfront license fee actually received by IPR in connection with the CPaiR intellectual property and 20% of the quarterly revenue actually received by IPR in connection with such intellectual property. If IPR does not pay a minimum of $1,000,000 to CPaiR within a period of three years from the Effective date, the license agreement will terminate. IPR has the right to pay the difference between the amounts paid by IPR and the minimum payment of $1,000,000. Under the terms of the agreement, IPR was not required to pay an upfront license fee. American Cryostem Corp. Effective January 27, 2012, IPR entered into a License Agreement with American Cryostem Corp. (“ACSC”) to acquire the rights to and to distribute certain intellectual property in China and Brazil. The term of the License Agreement shall be for one year. The term shall automatically renew for an additional one-year term unless either party notifies the other that it does not desire to renew the License Agreement. Under the License Agreement, any distributer or sub-licensee, engaged by IPR, must pay 25% of its quarterly gross revenue which shall be split 50/50 between IPR and ACSC. In the event that IPR receives any upfront license fee from a sub-licensee, IPR is required to pay to ACSC 50% of that upfront license fee. Under the terms of the agreement, IPR was not required to pay an upfront license fee.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 3 - Property and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at December 31, 2016 and 2015: As of December 31, 2016 2015 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 8,774 8,774 78,232 78,232 Less accumulated depreciation 62,407 46,575 $ 15,825 $ 31,657 Depreciation expense for the years ended December 31, 2016 and 2015 was $15,833 and $14,773, respectively. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations.

Notes Payable and Long Term Loa

Notes Payable and Long Term Loan	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Notes Payable and Long Term Loan	Note 4 - Notes payable and Long Term Loan Notes Payable In October 2013, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 125,000 shares of its common stock for each unit. In July 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 50,000 shares of its common stock for each unit. In October 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 50,000 shares of its common stock for each unit. In August 2015, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 100,000 shares of its common stock for each unit. At issuance of each private placement note payable agreement, the Company records a discount at the greater of the principal balance of the note payable or the fair value of the common stock issued in connection with the note. The discount is amortized over the life of each note, one year. During the year ended December 31, 2016, the Company did not issue notes in connection with these private placements. During the year ended December 31, 2015, the Company issued promissory notes for an aggregate principal of approximately $615,000, and recorded discounts amounting to $223,551 in connection with these. As of December 31, 2016, notes payable outstanding under these private placements are $1,075,500. Of this amount, $1,065,000 of the outstanding balance on these notes are past maturity. During the years ended December 31, 2016 and 2015, the Company issued ten and twelve, respectively, Convertible Debentures (“Variable Debentures”) for cash of $1,1421,778 and $921,250 with ori During the year ended December 31, 2016, the Company entered into $70,000 in 2 notes payable with an unrelated party and issued 140,000 shares in connection with these notes. The notes bear interest at 10% per year and mature in May 2017. At December 31, 2016, $60,000 remained outstanding on this note. During July 2015, the Company entered into a settlement agreement with the holder of a $100,000 Variable Debenture wherein the Note was exchanged for 900,000 shares of common stock, with the restriction that the shares may be sold from time to time at various prices of $0.60 and above. During December 2015, the Company entered into a settlement agreement with the holder of a $38,000 Variable Debenture wherein the Company repaid in full the Note balance with a cash payment of $56,590. In accordance with ASC 470-50, Debt Modifications and Extinguishments, the Company recognized a $127,674 net loss on extinguishment of debt in connection with these settlement agreements. As of December 31, 2016, the Company had notes payable to related parties amounting to $170,000. Refer to Note 6 – Related Party Transactions. As of December 31, 2016 2015 Notes payable at beginning of period $ 2,333,751 $ 1,377,416 Notes payable issued 1,776,895 1,586,250 Default interest added to note payable 62,500 - Settlements on note payable (55,000 ) - Repayments of notes payable in cash (241,500 ) (138,000 ) Less amounts converted to stock (682,690 ) (491,915 ) Notes payable at end of period 3,193,956 2,333,751 Less debt discount (1,145,849 ) (799,307 ) $ 2,048,107 $ 1,534,444 Notes payable issued to related parties $ 170,000 $ 245,000 Notes payable issued to non-related parties $ 1,878,107 $ 1,289,444 The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total December 31, 2017 3,023,956 170,000 3,193,956 Total $ 3,023,956 $ 170,000 $ 3,193,956 Long Term Loan The Company has financed the purchase of an automobile. The maturity dates on the loan are as follows: Twelve months ending, December 31, 2017 $ 12,395 December 31, 2018 $ 4,221 $ 16,616 Current portion $ 12,395 Long term portion $ 4,221 Acquisition Payable In connection with the Company’s acquisition of IPR in 2012, IPR recorded a $155,000 long-term acquisition payable for costs that were not paid at closing. These payable is non-interest bearing and IPR agreed to make payments up to 25% of the proceeds from any private placement or gross profits earned by IPR until the obligation is satisfied. The percentage of the proceeds to be paid is at the sole discretion of IPR’s Chief Executive Officer and the ex-Chief Executive Officer of the Company based on the liquidity of the Company. Effective Interest Rate During the year ended December 31, 2016 and 2015, the Company’s effective interest rate was 89% and 83%, respectively.

Shareholders' Deficit

Shareholders' Deficit	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Shareholders' Deficit	Note 5 - Shareholders’ Deficit Common Stock The Company has entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulate a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant is issued a prorated number of shares of common stock at the beginning of the contract, which the consultant earns over a three-month period. At the anniversary of each quarter, the consultant is issued a new allotment of common stock during the first 3 years of engagement. In accordance with ASC 505-50 – Equity-Based Payment to Non-Employees, the common stock shares issued to the consultant are valued upon their vesting, with interim estimates of value as appropriate during the vesting period. During the year ended December 31, 2016, the Company issued 2,775,000 shares of common stock with a value of $953,250 related to these consulting agreements. During the year ended December 31, 2016, the Company also issued 7,113,760 shares of common stock with a value of $1,411,722 for additional services and fees. During the year ended December 31, 2016, the Company issued pursuant to a private placement offering 9,194,940 shares of common stock and the same number of warrants for cash of $1,128,750 and conversion of notes and accrued interest in the amount of $308,608. The Company also issued 566,327 shares of common stock for cash of $107,079 and 9,476,582 shares of common stock for the conversion of notes and accrued interest in the amount of $1,957,717. Also, during the year ended December 31, 2016, the Company issued 266,617 shares of common stock valued at $111,661 related to the extension of outstanding notes and lock-up agreements and 140,000 shares valued at $11, 080 were issued in connection with $70,000 notes payable. During the year ended December 31, 2015, the Company granted 6,519,286 shares for services performed by consultants and recorded expense of $728,750. During the year ended December 31, 2015, the Company issued 1,855,000 shares of common stock to the purchasers of notes. The share issuance was valued at $223,551. During the year ended December 31, 2015, the Company issued 800,000 shares of its common stock at a fair value of $61,750 on the extension of notes payable. The fair value of stock issued on the extension of notes starting on July 1, 2015 was based on the market price of the stock on the date of grant since significant trading started at that time. In addition, during the year ended December 31, 2015, the Company issued 13,450,592 shares of common stock on the conversion of notes in an amount of $491,915 and accrued interest of $52,623. Through the six months ended June 30, 2015, the Company revalued the shares based on low trading volume to $0.001. The fair value of stock issued for services and as for non-cash consideration starting on July 1, 2015 was based on the market price of the stock on the date of grant since significant trading started at that time. Warrants During the year ended December 31, 2016, in conjunction with the sale of Common Stock, the Company issued five-year common stock purchase warrants to acquire up to 9,194,940 shares of common stock with exercise prices ranging from $0.0825 to $0.90 per share. In March 2016, the Company issued a two-year common stock purchase warrant exercisable into up to 300,000 shares of common stock with an exercise price of $0.81 for services provided by a consultant. The value of these warrants was recorded as non-cash expense in an amount of $40,000 using the Black Sholes Option pricing method. The Variable Debentures issued by the Company each have a provision requiring the Company to reserve a variable amount of shares of common stock for when the holder of the Variable Debenture converts. As of December 31, 2016, the Company has reserved approximately 94,870,000 of common shares related to the outstanding debentures. A summary of the status of the warrants granted under these agreements at December 31, 2016, and changes during the year then ended is presented below: Warrants Weighted Average Exercise Shares Price Outstanding, December 31, 2015 - $ - Granted 9,494,940 $ 0.328 Expired - $ - Exercised - $ - Outstanding, December 31, 2016 9,494,940 $ 0.328 Exercisable, December 31, 2016 9,494,940 $ 0.328 Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Warrants $ 0.0825-0.1695 3,342,963 4.89 $ 0.116 3,342,963 $ 0.116 $ 0.195-0.30 2,962,114 4.57 $ 0.232 2,962,114 $ 0.232 $ 0.452-0.5775 652,489 4.14 $ 0.529 652,489 $ 0.529 $ 0.5805-0.6525 1,597,314 4.24 $ 0.603 1,597,314 $ 0.603 $ 0.6735-0.90 940,060 4.26 $ 0.773 940,060 $ 0.773 9,494,940 4.57 $ 0.328 9,494,940 $ 0.328 Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. As of December 31, 2016, there were 1,000 shares of Series AA Preferred stock outstanding.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions Two executive officers and the operations manager of the Company have agreed to defer their compensation until cash flow improves. As of December 31, 2016, the balance of their deferred compensation is approximately $1,861,327. From time-to-time officers and the operations manager of the Company advance monies to the Company to cover costs. During the year ended December 31, 2016, officers advanced $12,618 of funds to the Company of which $10,300 were repaid during the year. The balance of short-term advances due to two officers and executives of the Company at December 31, 2016 is $5,823. During the year ended December 31, 2015, an officer and executive of the Company entered into a note payable agreement for $50,000, and the principal and interest of a $96,000 note payable to another related party was converted into 350,000 shares of common stock. During the year ended December 31, 2016, the Company repaid the principal and interest of a $75,000 note payable to its operations manager. At December 31, 2016, notes payable remain outstanding to one officer and executive of the Company, in the amount of $170,000.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 - Income taxes The Company files income tax returns with the Internal Revenue Service (“IRS”) and various state jurisdictions. For jurisdictions in which tax filings are prepared, the Company is subject to income tax examinations by state tax authorities and federal tax authorities for all tax years. The deferred tax assets are mainly comprised of net loss carryforwards. As of December 31, 2016, the Company had approximately $9,743,000 of federal net operating loss carryforwards, that it can use to offset a certain amount of taxable income in the future. These federal net operating loss carryforwards begin to expire in 2029. The resulting deferred tax asset is offset by a 100% valuation allowance due to the uncertainty of its realization. A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2016 and 2015: 2016 2015 Income tax computed at federal statutory tax rate -34.0 % -34.0 % Change in valuation allowance 39.8 % 39.8 % State taxes, net of federal benefit -5.8 % -5.8 % Total 0.0 % 0.0 % The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before provision for income taxes relates to the change in the valuation allowance. The Company has adopted the accounting standards that clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled $0 for the years ended December 31, 2016 and 2015.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 - Commitments and Contingencies Legal matters The Company may become involved in various legal proceedings in the normal course of business.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 9 - Subsequent Events. Subsequent to December 31, 2016, an aggregate of 747,336 Subsequent to December 31, 2016, the Company raised $334,034 from 21 14,518,444 Subsequent to December 31, 2016, the Company entered into agreements to raise $2,737,000 of Convertible Redeemable Notes with one existing investor of which $518,750 has been received to date. These notes have a 10% per annum interest rate, favorable redemption options and leak out provisions restricting the total sales to no more than 20% of the total daily volume of the company’s stock in any given day. Subsequent to December 31, 2016, the Company agreed to an assignment of the Bellridge Capital LLC Notes to its sole existing variable securities investor with favorable redemption options and leak out provisions. To date, the investor has paid Bellridge $334,255 to acquire the remainder of the first note and has agreed to acquire the remaining two notes. Subsequent to December 31, 2016, the Company converted $ 708,226 73,791,386 Subsequent to December 31, 2016, the Company’s authorized share count was increased to 500,000,000. Subsequent to December 31, 2016, On February 7, 2017, we filed a certificate of designation (“the “Designation”) relating to our newly designated Series B Convertible Preferred Stock (the “B Preferred”). The Designation created 50,000 shares of B Preferred from the 5,000,000 shares of preferred stock that our board may designate from time to time. Each share of B Preferred has a liquidation preference and stated value of $100, is convertible into units of common stock and warrants analogous to the common stock and warrants issued in our ongoing private placement commencing. Such conversion right commences six months from the date of issuance, but the pricing terms are fixed on the date of investment. As a result of these issuances the total number of shares outstanding is 221,543,486.

Nature of Business and Summar16

Nature of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, and WeHealAnimals, Inc. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has recurring net losses and working capital deficits. The Company has raised approximately $2.7 million in debt and equity financing for the year ended December 31, 2016. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its common stock, has engaged a broker/dealer to raise additional capital and is seeking out profitable companies.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2016, cash and cash equivalents did not exceed FDIC limits.
Property Plant and Equipment	Property plant and equipment Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five and seven years. Expenditures for repairs and maintenance are expensed as incurred.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows generated from the asset group to the recorded value of the asset group. If impairment is indicated, the asset is written down to its estimated fair value.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from its technology licensing and commercialization activities in accordance with paragraph 605-10-S99-1 of the FASB Accounting Standards Codification (“ASC”) for revenue recognition. The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the services have been rendered to the customer and accepted by the customer as completed, and (iii) collectability is reasonably assured.
Stock-Based Compensation	Stock-Based Compensation The Company measures stock-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of estimated forfeitures, over the vesting or service period, as applicable, of the stock award using the straight-line method. When our common stock is thinly traded, we have made estimates of the fair value of the common stock based not only on market prices but other factors such as financial condition and results of operations.
Income Taxes	Income Taxes The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.
Net Income (Loss) Per Share	Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method, and assumes the exercise or vesting of other dilutive securities, such as options, warrants and restricted stock using the treasury stock method, when dilutive. For the year ended December 31, 2016, the Company had 11,978,455 of weighted-average common shares relating to the convertible debt, under the if-converted method, however, these shares are not dilutive because the Company recorded a loss during the fiscal year.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2016 and 2015: Fair Value Measurements at December 31, 2016 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 1,927,752 $ 1,927,752 Total $ - $ - $ 1,927,752 $ 1,927,752 Fair Value Measurements at December 31, 2015 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 3,973,542 $ 3,973,542 Total $ - $ - $ 3,973,542 $ 3,973,542 The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the Derivative Liability Balance December 31, 2014 $ - Issuance of convertible debt 1,922,121 Settlements by debt extinguishment (480,056 ) Change in estimated fair value 2,531,477 Balance December 31, 2015 3,973,542 Issuance of convertible debt 2,525,515 Settlements by debt extinguishment (1,718,013 ) Change in estimated fair value (2,853,292 ) Balance December 31, 2016 $ 1,927,752
Derivative Liability	Derivative Liability The Company issued Variable Debentures during the years ended December 31, 2016 and 2015, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a derivative liability. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: For Year Ending December 31, 2016 2015 Expected term 1 year - 2 years 9 months - 3 years Exercise price $0.0113-$0.81 $0.03-$0.52 Expected volatility 176%-276% 159%-242% Expected dividends None None Risk-free interest rate 0.45%-1.06% 0.25%-1.06% Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.
Recent Accounting Standard Updates	Recent Accounting Standard Updates In August 2014, the FASB issued FASB ASU2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. FASB ASU 2014-15 changes to the disclosure of uncertainties about an entity’s ability to continue as a going concern. These changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. These changes became effective for the Company for the 2016 annual period. Management has evaluated the impact of the adoption of these changes and has determined there will be no material impact on the consolidated financial statements. This guidance will need to be applied by management at the end of each annual period and interim period therein to determine what, if any, impact there will be on the consolidated financial statements in a given reporting period. In April 2015, the FASB issued ASU No 2015-3, Simplifying the Presentation of Debt Issuance Costs. This update changes the presentation of debt issuance costs in the balance sheet. ASU 2015-03 requires debt issuance costs related to a recognized debt obligation to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability rather than being presented as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. In August 2015, the FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”. This ASU clarified guidance in ASC 2015-03 stating that the SEC staff would not object to a company presenting debt issuance costs related to a line-of-credit arrangement on the balance sheet as a deferred asset, regardless of whether there were any outstanding borrowings at period-end. This update is effective for annual and interim periods beginning after December 15, 2015, which required us to adopt these provisions in the first quarter of 2016. This update was applied on a retrospective basis, wherein the balance sheet of each period presented was adjusted to reflect the effects of applying the new guidance. The adoption of this guidance did not have a material impact on our consolidated financial statements. In November 2015, the FASB issued ASU No 2015-17, Income Taxes (Topic 740). The amendments in ASU 2015-17 change the requirements for the classification of deferred taxes on the balance sheet. Currently, GAAP requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company has early adopted this pronouncement for the fiscal reporting period ended December 31, 2016, and has reclassified the presentation of deferred income taxes in the prior period to conform with the current year classification in the consolidated balance sheets. As a result of the Company having recognized a valuation reserve for the entire deferred tax liability balance at December 31, 2016 and 2015, there is no impact of the presentation of deferred income taxes in our financial statements. In January 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The update intends to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information and addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The new standard affects all entities that hold financial assets or owe financial liabilities. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Management is evaluating the impact of the adoption of these changes will have on the consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

Nature of Business and Summar17

Nature of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Balances of Liabilities Measured at Fair Value	The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2016 and 2015: Fair Value Measurements at December 31, 2016 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 1,927,752 $ 1,927,752 Total $ - $ - $ 1,927,752 $ 1,927,752 Fair Value Measurements at December 31, 2015 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 3,973,542 $ 3,973,542 Total $ - $ - $ 3,973,542 $ 3,973,542
Changes in the Liabilities with Significant Unobservable Inputs	The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the Derivative Liability Balance December 31, 2014 $ - Issuance of convertible debt 1,922,121 Settlements by debt extinguishment (480,056 ) Change in estimated fair value 2,531,477 Balance December 31, 2015 3,973,542 Issuance of convertible debt 2,525,515 Settlements by debt extinguishment (1,718,013 ) Change in estimated fair value (2,853,292 ) Balance December 31, 2016 $ 1,927,752
Variable Debentures Black-Scholes Valuation Assumptions	The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: For Year Ending December 31, 2016 2015 Expected term 1 year - 2 years 9 months - 3 years Exercise price $0.0113-$0.81 $0.03-$0.52 Expected volatility 176%-276% 159%-242% Expected dividends None None Risk-free interest rate 0.45%-1.06% 0.25%-1.06% Forfeitures None None

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	The following is a summary of equipment, at cost, less accumulated depreciation at December 31, 2016 and 2015: As of December 31, 2016 2015 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 8,774 8,774 78,232 78,232 Less accumulated depreciation 62,407 46,575 $ 15,825 $ 31,657

Notes Payable and Long Term L19

Notes Payable and Long Term Loan (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Note Payables	Refer to Note 6 – Related Party Transactions. As of December 31, 2016 2015 Notes payable at beginning of period $ 2,333,751 $ 1,377,416 Notes payable issued 1,776,895 1,586,250 Default interest added to note payable 62,500 - Settlements on note payable (55,000 ) - Repayments of notes payable in cash (241,500 ) (138,000 ) Less amounts converted to stock (682,690 ) (491,915 ) Notes payable at end of period 3,193,956 2,333,751 Less debt discount (1,145,849 ) (799,307 ) $ 2,048,107 $ 1,534,444 Notes payable issued to related parties $ 170,000 $ 245,000 Notes payable issued to non-related parties $ 1,878,107 $ 1,289,444
Schedule of Maturity Dates of Notes Payable and Loan	The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total December 31, 2016 3,023,956 170,000 3,193,956 Total $ 3,023,956 $ 170,000 $ 3,193,956
Long-term Debt [Member]
Schedule of Maturity Dates of Notes Payable and Loan	The Company has financed the purchase of an automobile. The maturity dates on the loan are as follows: Twelve months ending, December 31, 2017 $ 12,395 December 31, 2018 $ 4,221 $ 16,616 Current portion $ 12,395 Long term portion $ 4,221

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Schedule of Warrants Outstanding	A summary of the status of the warrants granted under these agreements at December 31, 2016, and changes during the year then ended is presented below: Warrants Weighted Average Exercise Shares Price Outstanding, December 31, 2015 - $ - Granted 9,494,940 $ 0.328 Expired - $ - Exercised - $ - Outstanding, December 31, 2016 9,494,940 $ 0.328 Exercisable, December 31, 2016 9,494,940 $ 0.328
Schedule of Warrants Exercise Price Range	Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Warrants $ 0.0825-0.1695 3,342,963 4.89 $ 0.116 3,342,963 $ 0.116 $ 0.195-0.30 2,962,114 4.57 $ 0.232 2,962,114 $ 0.232 $ 0.452-0.5775 652,489 4.14 $ 0.529 652,489 $ 0.529 $ 0.5805-0.6525 1,597,314 4.24 $ 0.603 1,597,314 $ 0.603 $ 0.6735-0.90 940,060 4.26 $ 0.773 940,060 $ 0.773 9,494,940 4.57 $ 0.328 9,494,940 $ 0.328

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2016 and 2015: 2016 2015 Income tax computed at federal statutory tax rate -34.0 % -34.0 % Change in valuation allowance 39.8 % 39.8 % State taxes, net of federal benefit -5.8 % -5.8 % Total 0.0 % 0.0 %

Nature of Business and Summar22

Nature of Business and Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)shares
Debt and equity financing	$ 2,700,000
Unrecognized tax benefits
Antidilutive securities of weighted-average common shares | shares	11,978,455
Minimum [Member]
Property plant and equipment, estimated useful lives	5 years
Maximum [Member]
Property plant and equipment, estimated useful lives	7 years
Hanover Portfolio Acquisitions, Inc [Member]
Acquisitions description	On January 22, 2014 Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014.
Common stock, voting rights	Common Stock representing in excess of 50% of the total issued and outstanding voting power

Nature of Business and Summar23

Nature of Business and Summary of Significant Accounting Policies - Balances of Liabilities Measured at Fair Value (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Derivative liability	$ 1,927,752	$ 3,973,542
Total	1,927,752	3,973,542
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Derivative liability
Total
Significant Other Observable Inputs (Level 2) [Member]
Derivative liability
Total
Significant Unobservable Inputs (Level 3) [Member]
Derivative liability	1,927,752	3,973,542
Total	$ 1,927,752	$ 3,973,542

Nature of Business and Summar24

Nature of Business and Summary of Significant Accounting Policies - Changes in the Liabilities with Significant Unobservable Inputs (Details) - Derivative Liability [Member] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Liabilities with significant unobservable inputs , beginning balance	$ 3,973,542
Issuance of convertible debt	2,525,515	1,922,121
Settlements by debt extinguishment	(1,718,013)	(480,056)
Change in estimated fair value	(2,853,292)	2,531,477
Liabilities with significant unobservable inputs, ending balance	$ 1,927,752	$ 3,973,542

Nature of Business and Summar25

Nature of Business and Summary of Significant Accounting Policies - Variable Debentures Black-Scholes Valuation Assumptions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Expected dividends	0.00%	0.00%
Forfeitures
Minimum [Member]
Expected term	1 month	9 months
Exercise price	$ 0.0113	$ 0.03
Expected volatility	176.00%	159.00%
Risk-free interest rate	0.45%	0.25%
Maximum [Member]
Expected term	2 years	3 years
Exercise price	$ 0.81	$ 0.52
Expected volatility	276.00%	242.00%
Risk-free interest rate	1.06%	1.06%

License Agreements (Details Nar

License Agreements (Details Narrative) - USD ($)	Jan. 27, 2013	Nov. 11, 2011
CPAIR, Inc. [Member]
Royalties of sublease agreement paid percentage		20.00%
Percentage of gross revenues paid without subleasing		10.00%
Payment of upfront license fee		20.00%
Quarterly revenue paid		20.00%
Minimum payment to avoid termination		$ 1,000,000
Minimum license agreement term		21 years
Renewal term if not cancelled by either party 90 days in advance of expiration		1 year
Minimum required cancellation notification required before expiration date to extend license a year		90 days
Period for which the license agreement must be paid in		3 years
American Cryostem Corp. [Member]
Minimum license agreement term	1 year
Renewal term if not cancelled by either party 90 days in advance of expiration	1 year
Percent of quarterly gross revenue owed by distributor or sub-licensee	25.00%
Gross revenue split ratio	1
Percent of upfront license fee paid	50.00%

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 15,833	$ 14,773

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property and equipment, gross	$ 78,232	$ 78,232
Less accumulated depreciation	62,407	46,575
Property and equipment, net	15,825	31,657
Autos [Member]
Property and equipment, gross	64,458	64,458
Medical Equipment [Member]
Property and equipment, gross	5,000	5,000
Other Equipment [Member]
Property and equipment, gross	$ 8,774	$ 8,774

Notes Payable and Long Term L29

Notes Payable and Long Term Loan (Details Narrative)	1 Months Ended						12 Months Ended
	Jul. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)Integer	Aug. 31, 2015USD ($)shares	Oct. 31, 2014USD ($)shares	Jul. 31, 2014USD ($)shares	Oct. 31, 2013USD ($)shares	Dec. 31, 2016USD ($)Integershares	Dec. 31, 2015USD ($)Integershares	Dec. 31, 2014USD ($)	Dec. 31, 2012USD ($)
Proceeds from issuance of note payable							$ 1,491,778	$ 1,036,200
Debt instrument, interest rate							10.00%
Number of common stock shares issued for each units | shares							9,476,582	13,450,592
Note payable outstanding		$ 1,261,790					$ 1,878,107	$ 1,261,790
Convertible debentures outstanding amount							66,000
Note payable unrelated party							$ 70,000
Number of shares issued connection with note | shares							70,000
Debt maturity description							matures in May 2017
Remaining outstanding debt							$ 60,000
Percentage of note purchased at original issue discount		83.00%					89.00%	83.00%
Debt exchange for shares value							$ 1,957,717	$ 1,029,539
Loss on extinguishment of debt							(488,149)	(127,674)
Note payable to related parties		$ 245,000					$ 170,000	245,000
IPR [Member]
Long-term acquisition payable for costs not paid at closing										$ 155,000
Percentage of proceeds from any private placement or gross profits										25.00%
Seven Convertible Debentures [Member] | Settlement Agreement [Member]
Number of common stock shares issued for each units | shares	900,000
Convertible debentures outstanding amount		56,590						$ 56,590
Debt exchange for shares value	$ 100,000
Debt conversion price per share | $ / shares	$ 0.60
Repayment of convertible debt		38,000
Loss on extinguishment of debt		127,674
Seven Convertible Debentures [Member] | Minimum [Member]
Debt term							9 months	9 months
Initial principal annual interest rates							6.00%	6.00%
Debt discount rate percentage							25.00%	25.00%
Prepayment of note period							0 days	0 days
Percentage of issuance note of premium							120.00%	120.00%
Seven Convertible Debentures [Member] | Maximum [Member]
Debt term							3 years	3 years
Initial principal annual interest rates							10.00%	10.00%
Debt discount rate percentage							53.00%	53.00%
Prepayment of note period							180 days	180 days
Percentage of issuance note of premium							145.00%	145.00%
Notes Payable [Member]
Debt discount amount		(799,307)					$ (1,145,849)	$ (799,307)
Note payable outstanding							1,065,000
Note payable unrelated party		2,333,751					3,193,956	2,333,751	$ 1,377,416
Debt exchange for shares value							(682,690)	(491,915)
Seven Convertible Debentures [Member]
Debt instrument face amount		$ 921,250					$ 1,421,778	$ 921,250
Debt instrument, interest rate		10.00%					10.00%	10.00%
Debt discount amount		$ 859,071					$ 1,723,471	$ 859,071
Number of convertible debentures issued | Integer		12					10	12
Convertible debentures outstanding amount							$ 1,888,456
Private Placement [Member]
Debt instrument face amount		$ 615,000	$ 500,000	$ 500,000	$ 500,000	$ 500,000		$ 615,000
Proceeds from issuance of note payable			$ 25,000	$ 25,000	$ 25,000	$ 25,000
Debt instrument, interest rate			10.00%	10.00%	10.00%	10.00%
Debt term			1 year	1 year	1 year	1 year
Number of common stock shares issued for each units | shares			100,000	50,000	50,000	125,000
Debt discount amount		$ 223,551						$ 223,551
Note payable outstanding							$ 1,075,500

Notes Payable and Long Term L30

Notes Payable and Long Term Loan - Schedule of Notes Payables (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Repayments of notes payable in cash	$ 166,500	$ 138,000
Less amounts converted to stock	1,957,717	1,029,539
Notes payable at end of period	70,000
Notes Payable [Member]
Notes payable at beginning of period	2,333,751	1,377,416
Notes payable issued	1,776,895	1,586,250
Default interest added to note payable	62,500
Settlements on note payable	(55,000)
Repayments of notes payable in cash	(241,500)	(138,000)
Less amounts converted to stock	(682,690)	(491,915)
Notes payable at end of period	3,193,956	2,333,751
Less debt discount	(1,145,849)	(799,307)
Note payable, net	2,048,107	1,534,444
Notes payable issued to related parties	170,000	245,000
Notes payable issued to non-related parties	$ 1,878,107	$ 1,289,444

Notes Payable and Long Term L31

Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable and Loan (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
December 31, 2017	$ 3,193,956
Total	3,193,656
Current portion	12,395
Long term portion		$ 27,654
Long-term Debt [Member]
December 31, 2017	12,395
December 31, 2018	4,221
Total	16,616
Current portion	12,395
Long term portion	4,221
Non-Related Parties [Member]
December 31, 2017	3,023,956
Total	3,023,956
Related Parties [Member]
December 31, 2017	170,000
Total	$ 170,000

Shareholders' Deficit (Details

Shareholders' Deficit (Details Narrative) - USD ($)	1 Months Ended					12 Months Ended
	Mar. 31, 2016	Aug. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Feb. 22, 2013
Common stock issued, value						$ 1,128,750
Number of common stock shares issued for additional services and fees						7,113,760
Number of common stock issued for additional services and fees						$ 1,411,722
Number of warrants issued for cash						1,128,750
Private placement units issued for conversion of notes payable and accrued interest						$ 308,608
Shares issued for cash, shares						566,327
Shares issued for cash						$ 107,079	$ 139,091
Shares issued for conversion of notes payable and accrued interest, shares						9,476,582	13,450,592
Shares issued for conversion of notes payable and accrued interest						$ 1,957,717	$ 1,029,539
Shares issued for services, shares							6,519,286
Shares issued for services						$ 2,364,971	$ 728,750
Shares issued with note payable, shares						140,000	1,855,000
Shares issued with note payable						$ 11,080	$ 223,551
Number of shares issued connection with note						70,000
Fair value of stock issued on extension of notes, shares							800,000
Fair value of stock issued on extension of notes							$ 61,750
Accrued interest							$ 52,623
Low trading volume per share based on share						$ 0.0001	$ 0.0001	$ 0.0001
Warrants term	2 years					5 years
Warrants issued to purchase common stock	300,000					9,194,940
Warrant exercise price	$ 0.81
Value of warrants	$ 40,000
Reserved common shares						94,870,000
Super AA super voting preferred stock, authorized						1,000,000	1,000,000		1,000,000
Super AA super voting preferred stock, par value						$ 0.0001	$ 0.0001		$ 0.0001
Super AA super voting preferred stock, outstanding						1,000	1,000		(100,000)
Minimum [Member]
Warrant exercise price						$ 0.0825
Maximum [Member]
Warrant exercise price						$ 0.90
Extension of Outstanding Notes and Lock-up Agreements [Member]
Common stock, shares issued						266,617
Common stock issued, value						$ 111,661
Private Placement [Member]
Common stock, shares issued						9,194,940
Shares issued for conversion of notes payable and accrued interest, shares		100,000	50,000	50,000	125,000
Consulting Agreements [Member]
Common stock, shares issued						2,775,000
Common stock issued, value						$ 953,250

Shareholders' Deficit - Schedul

Shareholders' Deficit - Schedule of Warrants Outstanding (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Shares outstanding, beginning balance | shares
Shares outstanding, granted | shares	9,494,940
Shares outstanding, expired | shares
Shares outstanding, exercised | shares
Shares outstanding, ending balance | shares	9,494,940
Shares outstanding, exercisable | shares	9,494,940
Weighted average exercise price, beginning balance | $ / shares
Weighted average exercise price, granted | $ / shares	0.328
Weighted average exercise price, expired | $ / shares
Weighted average exercise price, exercised | $ / shares
Weighted average exercise price, ending balance | $ / shares	0.328
Weighted average exercise price, exercisable | $ / shares	$ 0.328

Shareholders' Deficit - Sched34

Shareholders' Deficit - Schedule of Warrants Exercise Price Range (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Number of warrants outstanding | shares	9,494,940
Weighted average remaining contractual life	4 years 6 months 26 days
Weighted average exercise price	$ 0.328
Number of warrants exercisable | shares	9,494,940
Weighted average exercise price exercisable	$ 0.328
Price Range 1 [Member]
Range of exercise prices, lower limit	0.0825
Range of exercise prices. upper limit	$ 0.1695
Number of warrants outstanding | shares	3,342,963
Weighted average remaining contractual life	4 years 10 months 21 days
Weighted average exercise price	$ 0.116
Number of warrants exercisable | shares	3,342,963
Weighted average exercise price exercisable	$ 0.116
Price Range 2 [Member]
Range of exercise prices, lower limit	0.195
Range of exercise prices. upper limit	$ 0.30
Number of warrants outstanding | shares	2,962,114
Weighted average remaining contractual life	4 years 6 months 26 days
Weighted average exercise price	$ 0.232
Number of warrants exercisable | shares	2,962,114
Weighted average exercise price exercisable	$ 0.232
Price Range 3 [Member]
Range of exercise prices, lower limit	0.452
Range of exercise prices. upper limit	$ 0.5775
Number of warrants outstanding | shares	652,489
Weighted average remaining contractual life	4 years 1 month 21 days
Weighted average exercise price	$ 0.529
Number of warrants exercisable | shares	652,489
Weighted average exercise price exercisable	$ 0.529
Price Range 4 [Member]
Range of exercise prices, lower limit	0.5805
Range of exercise prices. upper limit	$ 0.6525
Number of warrants outstanding | shares	1,597,314
Weighted average remaining contractual life	4 years 2 months 27 days
Weighted average exercise price	$ 0.603
Number of warrants exercisable | shares	1,597,314
Weighted average exercise price exercisable	$ 0.603
Price Range 5 [Member]
Range of exercise prices, lower limit	0.6735
Range of exercise prices. upper limit	$ 0.90
Number of warrants outstanding | shares	940,060
Weighted average remaining contractual life	4 years 3 months 4 days
Weighted average exercise price	$ 0.773
Number of warrants exercisable | shares	940,060
Weighted average exercise price exercisable	$ 0.773

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Notes payable - related parties	$ 170,000	$ 245,000
Number of converted shares of common stock	9,476,582	13,450,592
Two Officers and Executives [Member]
Deferred compensation	$ 1,562,000
Due to officer	5,823
Officers [Member]
Related party advances	12,618
Repayment of related party debt	10,300
Officers and Executives [Member]
Repayment of related party debt		$ 96,000
Notes payable - related parties		$ 50,000
Number of converted shares of common stock		350,000
Repayment of debt	75,000
One Officers and Executive [Member]
Notes payable - related parties	$ 170,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes Details Narrative
Federal net operating loss carry forwards	$ 9,743,000
Federal net operating loss carry forwards expire date	begin to expire in 2029
Deferred tax, valuation allowance percentage	100.00%
Interest and penalties	$ 0	$ 0

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation Details
Income tax computed at federal statutory tax rate	(34.00%)	(34.00%)
Change in valuation allowance	39.80%	39.80%
State taxes, net of federal benefit	(5.80%)	(5.80%)
Total	0.00%	0.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)Investorsshares	Dec. 31, 2015shares	Aug. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013
Issuance of shares of common stock, amount | $	$ 1,128,750
Debt rate	10.00%
Convertible debt | $	$ 66,000
Common stock, shares authorized	250,000,000	250,000,000
Preferred stock, shares issued	1,000	1,000
Common stock shares outstanding	134,336,637	104,803,401
Private Placement [Member]
Debt rate			10.00%	10.00%	10.00%	10.00%
Subsequent Event [Member]
Convertible debt | $	$ 708,226
Common stock shares outstanding	221,543,486
Subsequent Event [Member] | Series B Preferred Stock [Member]
Preferred stock, shares designated	50,000
Preferred stock, shares issued	5,000,000
Preferred stock liquidation preference value | $	$ 100
Subsequent Event [Member] | Maximum [Member]
Common stock, shares authorized	500,000,000
Subsequent Event [Member] | Convertible Redeemable Notes [Member]
Issuance of convertible notes payable | $	$ 2,737,000
Debt rate	10.00%
Sales percentage	20.00%
Subsequent Event [Member] | Private Placement [Member]
Issuance of shares of common stock, amount | $	$ 334,034
Number of investors | Investors	21
Warrants issued in private placements	14,518,444
Subsequent Event [Member] | One Existing Investor [Member]
Issuance of convertible notes payable | $	$ 518,750
Subsequent Event [Member] | Bellridge [Member] | Remaining Two Notes [Member]
Payments to acquire notes | $	$ 334,255
Subsequent Event [Member] | Restricted Common Stock [Member]
Issuance of restricted common stock, shares	73,791,386
Subsequent Event [Member] | Restricted Common Stock [Member] | Independent Contractors [Member]
Issuance of restricted common stock, shares	747,336